Prevalence of metabolic syndrome among patients with schizophrenia in Singapore

Annals of the Academy of Medicine Singapore

Volumn 41, Issue 10, 2012, Pages 457-462

  Lee, Jimmy ^a   Nurjono, Milawaty ^a   Wong, Audrey ^a   Salim, Agus ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Mental illness; Obesity; Smoking

Indexed keywords

CHLORPROMAZINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; SINGAPORE; SMOKING; WAIST CIRCUMFERENCE;

EID: 84868562520     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14.
2. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007;64:242-9.
3. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 2010 Nov;123:234-43.
4. McCreadie RG, Scottish Schizophrenia Lifestyle G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-9.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, American Heart Association; National Heart, Lung, and Blood Institute, et al., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation 2005;112:2735-52.
6. Taslim S, Tai ES. The relevance of the metabolic syndrome. Ann Acad Med Singapore 2009;38:29-5.
7. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, CLAMORS Study Collaborative Group, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90:162-73.
8. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in fi rst-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008;101:295-303.
9. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009;120:274-80.
10. Koponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, Isohanni MK, et al. The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry 2010;11:262-7.
11. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamashita H, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010;123:244-50.
12. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in fi rst episode schizophrenia-a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008;101:266-72.
13. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 2009;43:1106-11.
14. Tirupati S, Chua LE. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 2007;15:470-3.
15. Lee J, Ma S, Heng D, Tan CE, Chew SK, Hughes K, et al. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care 2007;30:343-7.
16. Lee J, Heng D, Ma S, Chew SK, Hughes K, Tai ES. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf) 2008;69:225-30.
17. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157-63.
18. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7.
19. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
20. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, et al. Modifi cation of the NCEP ATP III defi nitions of the metabolic syndrome for use in Asians identifi es individuals at risk of ischemic heart disease. Atherosclerosis 2006;186:367-73.
21. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119:101-9.
22. Khoo CM, Liew CF, Chew SK, Tai ES. The impact of central obesity as a prerequisite for the diagnosis of metabolic syndrome. Obesity (Silver Spring) 2007;15:262-9.
23. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68 Suppl 4:8-13.